The IAVI C114 study is a Phase 1 clinical trial evaluating the safety and immune response of an experimental HIV vaccine, GRAdHIVNE1.
1. What is the IAVI C114 study about?
The IAVI C114 study is a Phase 1 clinical trial evaluating the safety and immune response of an experimental HIV vaccine, GRAdHIVNE1, which uses a novel viral vector to deliver HIV components to the immune system.
2. Where is the study taking place?
The trial is being conducted at three clinical research sites in Southern Africa:
● Mutala Trust, Harare, Zimbabwe
● Desmond Tutu Health Foundation (DTHF), Cape Town, South Africa
● Africa Health Research Institute (AHRI), Durban, South Africa
3. Who is participating in the trial?
Approximately 120 healthy adults aged 18–50 years will participate, including:
● 48 people living with HIV (PLWH) who are stable on antiretroviral treatment (ART)
● 72 people living without HIV (PLWoH)
4. What does participation involve?
Participants will receive one or two doses of the study vaccine or a placebo via intramuscular injection and will be followed for approximately 19 months with regular clinic visits.
5. What are the main goals of the study?
The trial aims to answer three key questions:
● Is the GRAdHIVNE1 vaccine safe?
● Does the vaccine produce immune responses that could help protect against HIV?
● How do immune responses compare between people living with HIV and people living without HIV?
6. What is different about this vaccine?
GRAdHIVNE1 uses a harmless virus to deliver small, conserved parts of HIV (called epitopes) to the body’s immune system, targeting CD8+ T cell responses.
7. Is this a first for Africa?
While Africa has been involved in HIV vaccine trials before, this trial reflects a notable shift in leadership and implementation, with African researchers leading clinical design, site operations, and participant care.
8. Who are the partners in the study?
The trial is a collaborative effort between African clinical trial sites, research laboratories, and global collaborators, including IAVI, ReiThera, and the Ragon Institute.
9. How is participant safety being ensured?
Participant safety is being ensured through regular monitoring by experienced clinicians, an independent Safety Monitoring Committee, and ethics committee and regulatory authority approvals.
10. Who is funding this study?
The study is funded by the Gates Foundation.
11. What happens if the vaccine is successful?
If the vaccine is shown to be safe and produces promising immune responses, it may move into further clinical testing with larger populations.
12. Where can I learn more?
You can visit:
* www.acrnhealth.com
* www.iavi.org
* www.clinicaltrials.gov (NCT05922307)
For media inquiries, please contact: [email protected]



Fucking power machinesOffice porn galleries for freeUltimate pleasure 1977Free fucking north
peterFuck this hoseWhite females and asian menHarassment
letter sample sexual xnxx Vintage teen upskirt
sexOlder white women black cockFree teens having sex clipsNaked nudes beachesPorn tube cody laneTwo cocks pussy mouthNoni nudeAbsolutely download free movie porn xnxxy.cc Sims 2 penisUltra donkey pornInterracial gapingNude sara paxtonPee wee
herman bicycle replicaCandylist teensFred thompson gayIndian escorts in heathrowAsian facial
blowjobs xnxx Big cup pornAsian and indians under
apartheidDominican girls pornoChick licking cock and pussy videoTeen depression has not always been noticedNude supermodels wallpaperChinas adult
theme parkPics of fat pussyAre there glory holes in calgaryA touch of romance/ adult storeHer pregnant belly kept expanding cockZac efrons gay picturesFlorida sex offender sentencesFoxy
nudes clipsWhat is sexual frustrationAsian game golfSurat escortsGirls on girl eating pussyPorn video songsSweet pussy gamesNude piics of jlo